Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent, minimally invasive surgical procedure for severe benign prostatic hyperplasia (BPH). The primary clinical objective of HoLEP is to restore unobstructed urine flow by completely dissecting and removing the adenomatous central core of the prostate gland. By utilising a holmium:yttrium-aluminum-garnet (Ho:YAG) laser, the surgeon separates the obstructive tissue from the outer capsule along anatomical planes, followed by intravesical morcellation to clear the tissue from the bladder.

As established in the European Association of Urology (EAU) and American Urological Association (AUA) guidelines, HoLEP serves as a definitive standard of care for lower urinary tract symptoms (LUTS). Unlike thermal vaporization or resectoscopic techniques, HoLEP allows complete pathological tissue retrieval while minimizing intraoperative blood loss and operational recovery time.

HoLEP is conducted under general or regional anaesthesia in a surgical suite equipped for endourology. The patient is placed in the dorsal lithotomy position. A specialized continuous-flow laser resectoscope equipped with an endoscope and working channel is inserted through the urethra into the prostate cavity.

First, the surgeon inspects the prostatic urethra, bladder neck, and ureteral orifices. Using a high-powered holmium laser optical fiber (typically 550 microns), incision lines are made at the bladder neck at the 5 and 7 o'clock positions down to the prostatic capsule. The median lobe is enucleated from the surgical capsule working proximally from the verumontanum toward the bladder neck and retroverted into the urinary bladder cavity.

Next, identical anatomical dissection planes are developed for the left and right lateral lobes. The laser energy simultaneously cuts fibromuscular tissue and coagulates small blood vessels. Once all adenomatous lobes are enucleated and floating freely inside the urinary bladder, the laser resectoscope is exchanged for a mechanical tissue morcellator.

Under direct endoscopic visualization and continuous irrigation, the morcellator suction draws the floating prostate tissue into its bladed tip, fragmenting it into tiny pieces which are aspirated into a tissue collector for pathological examination. Finally, the surgeon performs careful inspection of the prostatic cavity for remaining bleeding vessels, achieves complete laser hemostasis, and inserts a 3-way urethral Foley catheter attached to continuous or intermittent bladder irrigation.

Evidence-based clinical advantages of HoLEP validated by EAU and AUA clinical practice guidelines include:

• Size-Independent Applicability: Effective for prostate glands of any volume, from under 30 grams to over 300 grams, eliminating the need for open or simple robotic prostatectomy in large glands.
• Superior Haemostasis and Reduced Bleeding: The coagulative properties of the holmium laser significantly reduce intraoperative transfusion rates compared to standard resection.
• Shorter Catheterisation and Hospitalisation: Average catheter removal time is under 24 hours, permitting same-day or next-day discharge in over 85% of cases.
• Durable Long-Term Results: Retransaction and reoperation rates following HoLEP are under 1% to 2% at 10-year follow-up, lower than those reported for transurethral resection of the prostate (TURP).
• Complete Tissue Retrieval: Unlike ablative techniques, enucleated tissue is morcellated and preserved for histological analysis to screen for incidental prostate carcinoma.
• Suitability for Anticoagulated Patients: Can be safely performed in high-risk cardiac patients managed on active antiplatelet or anticoagulant therapy under strict perioperative protocols.

The recovery timeline following HoLEP is structured into immediate, short-term, and complete stabilization phases:

• Days 1–3: The urethral catheter is typically removed within 12 to 24 hours. Patients may experience mild transient dysuria, frequency, and light rose-coloured hematuria. Strenuous activity and heavy lifting are strictly restricted.
• Weeks 1–2: Storage symptoms such as urgency and frequency persist as the prostatic cavity re-epithelialises. Hematuria usually resolves, though secondary transient light bleeding may occur around day 10 to 14 when eschar tissues slough off. Most patients return to light clerical work.
• Weeks 3–6: Significant objective improvements in peak urinary flow rate (Qmax) and post-void residual volume become apparent. Physical exertion, heavy lifting over 5 kg, and sexual intercourse may be gradually resumed as advised by the treating urologist.
• Months 3–6: Detrusor muscle adaptation completes, leading to resolution of pre-existing bladder urgency and nocturia. Complete histological and functional healing is established.

HoLEP is clinically indicated for moderate-to-severe lower urinary tract symptoms secondary to benign prostatic enlargement. Specific clinical entities and presentations addressed include:

• Benign Prostatic Hyperplasia (BPH): Moderate to severe bladder outlet obstruction refractory to medical management.
• Large Gland BPH: Prostates exceeding 80 to 100 grams where conventional transurethral resection is contraindicated due to bleeding risk or operational time constraints.
• Refractory Urinary Retention: Inability to void requiring temporary or long-term urinary catheterisation.
• Recurrent Hematuria: Persistent gross prostatic bleeding unresponsive to 5-alpha-reductase inhibitors.
• Secondary Renal Insufficiency: Obstructive uropathy leading to elevated serum creatinine or hydronephrosis.
• Recurrent Urinary Tract Infections (UTIs): Infections directly attributable to high post-void residual urine volume.
• Bladder Calculi: Secondary stone formation resulting from chronic urinary stasis.

Pre-procedure preparation for HoLEP involves comprehensive medical evaluation and pharmacological optimisation. Patients complete standard laboratory investigations including full blood count, kidney function tests, urinalysis, urine culture, and serum prostate-specific antigen (PSA). Cardiac clearance and pre-anaesthetic evaluation are performed.

Anticoagulant and antiplatelet medications (such as warfarin, clopidogrel, rivaroxaban, or aspirin) must be reviewed with the prescribing physician and urologist. Depending on individual thrombotic risk, these may be temporarily discontinued or bridged with low-molecular-weight heparin according to standardized clinical protocols.

Urinary tract infections must be identified and treated with culture-specific antibiotics prior to surgery. Fasting instructions require no solid food for 6 hours and no clear fluids for 2 hours prior to anaesthesia induction. A mild bowel preparation or rectal suppository may be administered on the morning of surgery to empty the rectum and facilitate clear intraoperative transrectal anatomy.

Complications of HoLEP are classified by clinical severity and onset timing:

Common and Mild: Transient dysuria, mild hematuria, urinary urgency, and temporary stress urinary incontinence (occurring in 5-15% of patients, typically resolving within 6-12 weeks). Retrograde ejaculation occurs in 75-80% of patients due to bladder neck resection.

Uncommon: Temporary urinary retention post-catheter removal requiring short-term re-catheterisation (2-5%), urinary tract infection (2-4%), and urethral stricture or bladder neck contracture (1-3%).

Rare and Serious: Capsular perforation with fluid extravasation (<1%), bladder wall injury during morcellation (<0.5%), severe hemorrhage requiring blood transfusion (<1%), and persistent long-term stress urinary incontinence requiring secondary intervention (<1%). Erectile dysfunction directly attributable to HoLEP is exceptionally rare (<1%) as the autonomic neurovascular bundles located outside the prostatic capsule are preserved.

The patient journey for HoLEP spans pre-operative assessment, surgical intervention, early catheter management, and mid-to-long-term urinary rehabilitation.

• Pre-Operative Evaluation: Patients undergo urinary symptom scoring, digital rectal examination, serum prostate-specific antigen (PSA) testing, transrectal or transperineal ultrasound, and uroflowmetry with post-void residual volume assessment.
• Surgical Intervention: Performed under general or spinal anaesthesia, the procedure involves endoscopically anatomical dissection of the prostate lobes into the bladder using the holmium laser fiber, followed by tissue morcellation.
• Immediate Post-Operative Phase: Continuous bladder irrigation is maintained via a three-way Foley catheter to prevent clot formation. Most patients have their catheter removed within 12 to 24 hours.
• Convalescence and Follow-Up: Initial recovery involves managing mild dysuria and transient urinary urgency. Full tissue healing and maximum urinary flow improvement are evaluated at 6 to 12 weeks post-operatively.